Cmb. Edwards et al., Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers, AM J P-ENDO, 281(1), 2001, pp. E155-E161
Citations number
46
Categorie Soggetti
Endocrinology, Nutrition & Metabolism
Journal title
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
Exendin-4 is a long-acting potent agonist of the glucagon-like peptide 1 (G
LP-1) receptor and may be useful in the treatment of type 2 diabetes and ob
esity. We examined the effects of an intravenous infusion of exendin-4 (0.0
5 pmol.kg(-1).min(-1)) compared with a control saline infusion in healthy v
olunteers. Exendin-4 reduced fasting plasma glucose levels and reduced the
peak change of postprandial glucose from baseline (exendin-4, 1.5 +/- 0.3 v
s. saline, 2.2 +/- 0.3 mmol/l, P< 0.05). Gastric emptying was delayed, as m
easured by the paracetamol absorption method. Volunteers consumed 19% fewer
calories at a free-choice buffet lunch with exendin-4 (exendin-4, 867 +/-
79 vs. saline 1,075 +/- 93 kcal, P = 0.012), without reported side effects.
Thus our results are in accord with the possibility that exendin-4 may be
a potential treatment for type 2 diabetes, particularly for obese patients,
because it acts to reduce plasma glucose at least partly by a delay in gas
tric emptying, as well as by reducing calorie intake.